Study suggests when dealing with fungi, it's best to attack from both sides

Feb 08, 2010

(PhysOrg.com) -- Each year, 83,000 life-threatening fungal infections cost us $2.6 billion. And this number will only go up as HIV infection, cancer chemotherapy, and organ transplants bump up the immune-compromised population where these fungi thrive.

Or maybe not.

Dr. David E. Levin, Professor of Molecular and Cell Biology at Boston University Henry M. Goldman School of Dental Medicine, and his team suggest in a new study that combining a therapy that increases pressure from within the fungal cell with existing antifungal drugs that weaken the , is the right mix to kill the infection.

After less than eight years on the market, clinical use of the new front line drugs for treating systemic fungal infections, known as echinocandins, is already being threatened by the appearance of clinical isolates with increased resistance to their antifungal activity. Echinocandin drugs, like caspofungin, attack the cell surface by interfering with cell wall biosynthesis. To enhance the sensitivity of fungal pathogens to these drugs, Dr. Levin looked to increase the internal force against the cell wall by exploiting a new target in fungi that is absent from human cells.

That target is what Dr. Levin calls the Rgc (abbreviation for Regulators of the glycerol channel) proteins. The paper is the first to describe the function of these proteins, which is to open a molecular “pressure valve” at the fungal cell surface. Inhibiting the Rgc proteins alone does not kill the fungal cells but makes them more sensitive to the effect of echinocandins.

“We envision a form of combination therapy for systemic fungal infections based on adding Rgc protein inhibitors to existing ,” Dr. Levin says.

The study, Identification of positive regulators of the yeast Fps1 glycerol channel, is available online in PLoS Genetics.

The mission of Boston University Henry M. Goldman School of Dental Medicine is to provide excellent education to dental professionals throughout their careers; to shape the future of dental medicine and dental education through research; to offer excellent health care services to the community; to participate in community activities; and to foster a respectful and supportive environment.

Explore further: Mycologist promotes agarikon as a possibility to counter growing antibiotic resistance

add to favorites email to friend print save as pdf

Related Stories

Gamma interferon could aid fight against fungal infections

Oct 31, 2007

Interferon, the “superhero” cure for viral infections, may be a strong weapon in the battle against fungal infections in immunocompromised patients, according to an article in the November issue of Microbiology Today.

Preventing Prostate Cancer to Bone Metastasis

Jul 13, 2009

(PhysOrg.com) -- In new research on prostate cancer to bone metastasis, Dr. Phillip Trackman of Boston University Henry M. Goldman School of Dental Medicine explains that the lysyl oxidase pro-peptide (LOX-PP) inhibits prostate ...

Mounting a multi-layered attack on fungal infections

Sep 08, 2009

Unravelling a microbe's multilayer defence mechanisms could lead to effective new treatments for potentially lethal fungal infections in cancer patients and others whose natural immunity is weakened.

Recommended for you

YEATS protein potential therapeutic target for cancer

Oct 23, 2014

Federal Express and UPS are no match for the human body when it comes to distribution. There exists in cancer biology an impressive packaging and delivery system that influences whether your body will develop cancer or not.

Precise and programmable biological circuits

Oct 23, 2014

A team led by ETH professor Yaakov Benenson has developed several new components for biological circuits. These components are key building blocks for constructing precisely functioning and programmable bio-computers.

User comments : 0